Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 422Lung Neoplasms 269Small Cell Lung Carcinoma 78Colorectal Neoplasms 75Breast Neoplasms 53Ovarian Neoplasms 50Neoplasms 49Melanoma 49Pancreatic Neoplasms 47Neoplasm Metastasis 39Squamous Cell Carcinoma of Head and Neck 37Stomach Neoplasms 33Head and Neck Neoplasms 30Prostatic Neoplasms 28Esophageal Neoplasms 28Carcinoma, Renal Cell 27Colonic Neoplasms 26Triple Negative Breast Neoplasms 25Endometrial Neoplasms 25Uterine Cervical Neoplasms 23Urinary Bladder Neoplasms 22Carcinoma, Hepatocellular 21Mesothelioma 17Mesothelioma, Malignant 16Sarcoma 15Rectal Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 13Lung Diseases 13Liver Neoplasms 13Carcinoma, Transitional Cell 13

Interventions

Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × Thoracic × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡